Clearwater Paper Reports Second Quarter 2022 Results
Clearwater Paper Corporation (NYSE:CLW) reported strong financial results for Q2 2022, with net sales of $526 million, up 30% year-over-year. Net income reached $15 million or $0.86 per diluted share, reversing last year's loss. Adjusted EBITDA rose to $63 million. The paperboard segment drove growth, with sales up 30% to $296 million, while the consumer products segment saw a 29% increase to $232 million. Despite challenges from inflation, the company aims to mitigate costs through operational enhancements.
- Net sales increased by 30% to $526 million in Q2 2022.
- Net income was $15 million, compared to a net loss of $52 million in Q2 2021.
- Adjusted EBITDA jumped to $63 million from $15 million in Q2 2021.
- Debt was reduced by $68 million in the quarter.
- Inflation impacts persist, affecting input costs in both segments.
SECOND QUARTER HIGHLIGHTS
- Delivered strong performance due to continued strength in paperboard and improvements in tissue
- Higher pricing in both businesses helping offset inflation
-
Net sales of
, up$526 million 30% compared to the second quarter of last year -
Net income of
, or$15 million per diluted share$0.86 -
Adjusted EBITDA of
$63 million -
Reduced net debt by
in the quarter and nearly$68 million year to date, achieved leverage target$100 million -
Repurchased nearly
of shares, with$4 million remaining under program$26 million
"We continued our trend of strong performance in the second quarter due to solid operational execution and improved pricing in both businesses,” said
OVERALL RESULTS
For the second quarter of 2022, Clearwater Paper reported net sales of
For the first six months of 2022, Clearwater Paper reported net sales of
Impacting the second quarter and first half of 2021, Clearwater Paper incurred impairment and other closure costs associated with the closure of its
Pulp and Paperboard Products Segment
Net sales in the Pulp and Paperboard Products segment were
Net sales in the Pulp and Paperboard Products segment were
Paperboard Sales Volumes and Prices:
• Paperboard sales volumes were 215,903 tons in the second quarter of 2022, an increase of
• Paperboard average net selling price increased
Consumer Products Segment
Net sales in the Consumer Products segment were
Net sales in the Consumer Products segment were
Retail Tissue Sales Volumes and Prices:
-
Retail tissue volumes sold were 76,604 tons in the second quarter of 2022, an increase of
25% compared to 61,497 tons in the second quarter of 2021. Retail tissue volumes sold were 152,030 tons in the first six months of 2022, an increase of25% compared to 132,259 tons in the first six months of 2021.
-
Retail tissue selling prices increased
8% to per ton in the second quarter of 2022, compared to$2,984 per ton in the second quarter of 2021. Retail tissue selling prices increased$2,755 8% to 2,928 per ton in the first six months of 2022, compared to per ton in the first six months of 2021.$2,757
COMPANY OUTLOOK
"Inflation remains a key theme in both of our businesses and is expected to persist into the third quarter. We are continuing with our efforts to offset these cost pressures with operational improvements and pricing. In addition, our focus on cashflow generation has enabled us to achieve our leverage target and we expect to discuss our capital allocation priorities later in the year,” concluded Kitch.
WEBCAST INFORMATION
ABOUT CLEARWATER PAPER
Clearwater Paper is a premier supplier of private brand tissue to major retailers, including grocery, club, mass merchants, and discount stores. In addition, the company produces bleached paperboard used by quality-conscious printers and packaging converters, and offers services that include custom sheeting, slitting, and cutting. Clearwater Paper's employees build shareholder value by developing strong relationships through quality and service.
USE OF NON-GAAP MEASURES
In this press release, the company presents certain non-GAAP financial information for the second quarter and first six months of 2022 and 2021, including adjusted income (loss) and Adjusted EBITDA. Because these amounts are not in accordance with GAAP, reconciliations to net income as determined in accordance with GAAP are included in the tables at the end of this press release. The company presents these non-GAAP amounts because management believes they assist investors and analysts in comparing the company's performance across reporting periods on a consistent basis by excluding items that the company does not believe are indicative of its core operating performance. In addition, the company uses Adjusted EBITDA: (i) as factors in evaluating management’s performance when determining incentive compensation, (ii) to evaluate the effectiveness of the company's business strategies, and (iii) because the company's credit agreement and the indentures governing the company's outstanding notes use metrics similar to Adjusted EBITDA to measure the company's compliance with certain covenants.
FORWARD-LOOKING STATEMENTS
This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended, including statements regarding product demand, cash generation, performance improvements, market conditions, debt reduction and share repurchases, and mitigation of inflationary pressures. These forward-looking statements are based on current expectations, estimates, assumptions, and projections that are subject to change, and actual results may differ materially from the forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: impact of the COVID-19 pandemic on our operations, our suppliers' operations and our customer demand; competitive pricing pressures for our products, including as a result of increased capacity as additional manufacturing facilities are operated by our competitors and the impact of foreign currency fluctuations on the pricing of products globally; customer acceptance and timing and quantity of purchases of our tissue products, including the existence of sufficient demand for and the quality of tissue produced by our expanded
|
|||||||||||||
Consolidated Statements of Operations |
|||||||||||||
(Unaudited) |
|||||||||||||
|
|
|
|
|
|||||||||
|
Quarter Ended |
|
Six Months Ended |
||||||||||
(In millions, except per-share data) |
|
2022 |
|
|
2021 |
|
|
|
2022 |
|
|
2021 |
|
Net sales |
$ |
526.4 |
|
$ |
406.4 |
|
|
$ |
1,014.6 |
|
$ |
832.3 |
|
Costs and expenses: |
|
|
|
|
|
||||||||
Cost of sales |
|
455.2 |
|
|
392.2 |
|
|
|
877.2 |
|
|
762.8 |
|
Selling, general and administrative expenses |
|
33.9 |
|
|
26.3 |
|
|
|
66.7 |
|
|
54.1 |
|
Other operating charges, net |
|
5.7 |
|
|
44.5 |
|
|
|
6.3 |
|
|
44.9 |
|
Total operating costs and expenses |
|
494.9 |
|
|
463.0 |
|
|
|
950.2 |
|
|
861.8 |
|
Income (loss) from operations |
|
31.5 |
|
|
(56.6 |
) |
|
|
64.4 |
|
|
(29.5 |
) |
Interest expense, net |
|
(10.7 |
) |
|
(9.3 |
) |
|
|
(19.3 |
) |
|
(18.6 |
) |
Debt retirement costs |
|
(0.3 |
) |
|
— |
|
|
|
(0.5 |
) |
|
— |
|
Other non-operating expense |
|
(1.4 |
) |
|
(2.5 |
) |
|
|
(2.8 |
) |
|
(5.0 |
) |
Total non-operating expense |
|
(12.4 |
) |
|
(11.8 |
) |
|
|
(22.7 |
) |
|
(23.6 |
) |
Income (loss) before income taxes |
|
19.1 |
|
|
(68.4 |
) |
|
|
41.7 |
|
|
(53.1 |
) |
Income tax provision (benefit) |
|
4.4 |
|
|
(16.7 |
) |
|
|
10.4 |
|
|
(13.5 |
) |
Net income (loss) |
$ |
14.7 |
|
$ |
(51.6 |
) |
|
$ |
31.3 |
|
$ |
(39.6 |
) |
|
|
|
|
|
|
||||||||
Net income (loss) per common share: |
|
|
|
|
|
||||||||
Basic |
$ |
0.87 |
|
$ |
(3.10 |
) |
|
$ |
1.86 |
|
$ |
(2.37 |
) |
Diluted |
|
0.86 |
|
|
(3.10 |
) |
|
|
1.83 |
|
|
(2.37 |
) |
|
|
|
|
|
|
||||||||
Average shares of common stock used to compute net income (loss) per share: (in thousands) |
|
|
|||||||||||
Basic |
|
16,849 |
|
|
16,685 |
|
|
|
16,788 |
|
|
16,678 |
|
Diluted |
|
17,078 |
|
|
16,685 |
|
|
|
17,080 |
|
|
16,678 |
|
|
||||||
Condensed Consolidated Balance Sheets |
||||||
(Unaudited) |
||||||
|
|
|
||||
(In millions) |
|
|
||||
Assets |
|
|
||||
Current assets: |
|
|
||||
Cash and cash equivalents |
$ |
69.5 |
|
$ |
25.2 |
|
Receivables, net |
|
187.3 |
|
|
167.4 |
|
Inventories |
|
287.7 |
|
|
277.7 |
|
Other current assets |
|
12.8 |
|
|
16.9 |
|
Total current assets |
|
557.2 |
|
|
487.2 |
|
Property, plant and equipment |
|
2,961.8 |
|
|
2,961.5 |
|
Accumulated depreciation |
|
(1,921.0 |
) |
|
(1,879.7 |
) |
Property, plant and equipment, net |
|
1,040.7 |
|
|
1,081.8 |
|
Other assets, net |
|
114.8 |
|
|
121.1 |
|
Total Assets |
$ |
1,712.7 |
|
$ |
1,690.1 |
|
|
|
|
||||
Liabilities and stockholders' equity |
|
|
||||
Current liabilities: |
|
|
||||
Current portion of long-term debt |
$ |
1.0 |
|
$ |
1.6 |
|
Accounts payable and accrued liabilities |
|
299.3 |
|
|
252.5 |
|
Total current liabilities |
|
300.3 |
|
|
254.1 |
|
Long-term debt |
|
589.9 |
|
|
637.6 |
|
Liability for pension and other postretirement employee benefits |
|
72.1 |
|
|
73.6 |
|
Deferred tax liabilities and other long-term obligations |
|
205.7 |
|
|
213.1 |
|
Total liabilities |
|
1,168.0 |
|
|
1,178.3 |
|
|
|
|
||||
Stockholders' equity: |
|
|
||||
Common stock |
|
— |
|
|
— |
|
Additional paid-in capital |
|
23.0 |
|
|
23.6 |
|
Retained earnings |
|
562.0 |
|
|
530.7 |
|
Accumulated other comprehensive loss, net of tax |
|
(40.3 |
) |
|
(42.6 |
) |
Total stockholders' equity |
|
544.7 |
|
|
511.7 |
|
Total liabilities and stockholders' equity |
$ |
1,712.7 |
|
$ |
1,690.1 |
|
|
|||||||||||||
Consolidated Statements of Cash Flows |
|||||||||||||
(Unaudited) |
|||||||||||||
|
Quarter Ended |
|
Six Months Ended |
||||||||||
(In millions) |
|
2022 |
|
|
2021 |
|
|
|
2022 |
|
|
2021 |
|
Operating activities |
|
|
|
|
|
||||||||
Net income (loss) |
$ |
14.7 |
|
$ |
(51.6 |
) |
|
$ |
31.3 |
|
$ |
(39.6 |
) |
Adjustments to reconcile net income (loss) to net cash flows provided by operating activities: |
|
|
|
|
|
||||||||
Depreciation and amortization |
|
25.7 |
|
|
26.8 |
|
|
|
51.2 |
|
|
53.7 |
|
Equity-based compensation expense |
|
4.9 |
|
|
0.7 |
|
|
|
5.5 |
|
|
3.1 |
|
Deferred taxes |
|
(1.9 |
) |
|
(21.4 |
) |
|
|
(4.1 |
) |
|
(21.8 |
) |
Defined benefit pension and other postretirement employee benefits |
|
0.8 |
|
|
1.5 |
|
|
|
1.5 |
|
|
3.2 |
|
Amortization of deferred debt costs and debt retirement |
|
0.7 |
|
|
0.5 |
|
|
|
1.3 |
|
|
0.9 |
|
Loss on sale or impairment associated with assets |
|
4.6 |
|
|
37.1 |
|
|
|
4.6 |
|
|
37.1 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
||||||||
(Increase) decrease in accounts receivable |
|
(11.3 |
) |
|
(12.9 |
) |
|
|
(21.8 |
) |
|
12.8 |
|
(Increase) decrease in inventory |
|
(5.8 |
) |
|
4.9 |
|
|
|
(10.0 |
) |
|
(24.8 |
) |
Decrease in other current assets |
|
4.2 |
|
|
4.5 |
|
|
|
4.2 |
|
|
4.4 |
|
Increase in accounts payable and accrued liabilities |
|
40.6 |
|
|
24.8 |
|
|
|
54.5 |
|
|
18.6 |
|
Other, net |
|
1.3 |
|
|
(0.6 |
) |
|
|
1.4 |
|
|
0.5 |
|
Net cash flows provided by operating activities |
|
78.5 |
|
|
14.3 |
|
|
|
119.5 |
|
|
48.1 |
|
Investing activities |
|
|
|
|
|
||||||||
Additions to property, plant and equipment, net |
|
(5.4 |
) |
|
(9.9 |
) |
|
|
(13.2 |
) |
|
(21.1 |
) |
Net cash flows used in investing activities |
|
(5.4 |
) |
|
(9.9 |
) |
|
|
(13.2 |
) |
|
(21.1 |
) |
Financing activities |
|
|
|
|
|
||||||||
Repayments of long-term debt |
|
(35.1 |
) |
|
(0.4 |
) |
|
|
(55.5 |
) |
|
(0.8 |
) |
Taxes paid related to net share settlement of equity awards |
|
(1.0 |
) |
|
(0.1 |
) |
|
|
(2.5 |
) |
|
(1.7 |
) |
Repurchases of common stock |
|
(3.9 |
) |
|
— |
|
|
|
(3.9 |
) |
|
— |
|
Other |
|
— |
|
|
— |
|
|
|
— |
|
|
0.5 |
|
Net cash flows used in financing activities |
|
(40.0 |
) |
|
(0.5 |
) |
|
|
(61.9 |
) |
|
(2.0 |
) |
|
|
|
|
|
|
||||||||
Increase in cash, cash equivalents and restricted cash |
|
33.1 |
|
|
3.8 |
|
|
|
44.4 |
|
|
25.0 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
37.5 |
|
|
58.2 |
|
|
|
26.2 |
|
|
36.9 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
70.6 |
|
$ |
62.0 |
|
|
$ |
70.6 |
|
$ |
62.0 |
|
|
|||||||||||||
Segment Information |
|||||||||||||
(Unaudited) |
|||||||||||||
|
|
|
|
||||||||||
|
Quarter Ended |
|
Six Months Ended |
||||||||||
(In millions) |
|
2022 |
|
|
2021 |
|
|
|
2022 |
|
|
2021 |
|
Segment net sales: |
|
|
|
|
|
||||||||
Pulp and Paperboard |
$ |
295.8 |
|
$ |
227.4 |
|
|
$ |
562.0 |
|
$ |
447.2 |
|
Consumer Products |
|
232.1 |
|
|
180.7 |
|
|
|
455.2 |
|
|
389.0 |
|
Eliminations |
|
(1.5 |
) |
|
(1.7 |
) |
|
|
(2.6 |
) |
|
(3.9 |
) |
Net sales |
$ |
526.4 |
|
$ |
406.4 |
|
|
$ |
1,014.6 |
|
$ |
832.3 |
|
|
|
|
|
|
|
||||||||
Operating income (loss): |
|
|
|
|
|
||||||||
Pulp and Paperboard |
$ |
52.0 |
|
$ |
13.0 |
|
|
$ |
102.3 |
|
$ |
38.0 |
|
Consumer Products |
|
3.5 |
|
|
(10.0 |
) |
|
|
4.4 |
|
|
7.9 |
|
Corporate and eliminations |
|
(18.2 |
) |
|
(15.0 |
) |
|
|
(36.0 |
) |
|
(30.5 |
) |
Other operating charges, net 1 |
|
(5.7 |
) |
|
(44.5 |
) |
|
|
(6.3 |
) |
|
(44.9 |
) |
Income (loss) from operations |
$ |
31.5 |
|
$ |
(56.6 |
) |
|
$ |
64.4 |
|
$ |
(29.5 |
) |
1 |
Other operating charges, net consist of amounts unrelated to ongoing core operating activities. Please refer to Note 8 within Clearwater Paper's Form 10-Q filed with the |
|
|||||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||||
Adjusted EBITDA |
|||||||||||||
(Unaudited) |
|||||||||||||
|
|||||||||||||
|
Quarter Ended |
|
Six Months Ended |
||||||||||
(In millions) |
|
2022 |
|
|
2021 |
|
|
|
2022 |
|
|
2021 |
|
Net income (loss) |
$ |
14.7 |
|
$ |
(51.6 |
) |
|
$ |
31.3 |
|
$ |
(39.6 |
) |
Add back: |
|
|
|
|
|
||||||||
Income tax provision (benefit) |
|
4.4 |
|
|
(16.7 |
) |
|
|
10.4 |
|
|
(13.5 |
) |
Interest expense, net |
|
10.7 |
|
|
9.3 |
|
|
|
19.3 |
|
|
18.6 |
|
Depreciation and amortization |
|
25.7 |
|
|
26.8 |
|
|
|
51.2 |
|
|
53.7 |
|
Other operating charges, net1 |
|
5.7 |
|
|
44.5 |
|
|
|
6.3 |
|
|
44.9 |
|
Debt retirement costs |
|
0.3 |
|
|
— |
|
|
|
0.5 |
|
|
— |
|
Other non-operating expense |
|
1.4 |
|
|
2.5 |
|
|
|
2.8 |
|
|
5.0 |
|
Adjusted EBITDA |
$ |
63.0 |
|
$ |
14.8 |
|
|
$ |
121.9 |
|
$ |
69.1 |
|
|
|
|
|
|
|
||||||||
Pulp and Paperboard segment income |
$ |
52.0 |
|
$ |
13.0 |
|
|
$ |
102.3 |
|
$ |
38.0 |
|
Depreciation and amortization |
|
9.2 |
|
|
9.0 |
|
|
|
18.5 |
|
|
18.0 |
|
Adjusted EBITDA Pulp and Paperboard |
$ |
61.2 |
|
$ |
22.0 |
|
|
$ |
120.8 |
|
$ |
56.0 |
|
|
|
|
|
|
|
||||||||
Consumer Products segment income (loss) |
$ |
3.5 |
|
$ |
(10.0 |
) |
|
$ |
4.4 |
|
$ |
7.9 |
|
Depreciation and amortization |
|
15.6 |
|
|
16.8 |
|
|
|
30.9 |
|
|
33.5 |
|
Adjusted EBITDA Consumer Products |
$ |
19.1 |
|
$ |
6.7 |
|
|
$ |
35.3 |
|
$ |
41.4 |
|
|
|
|
|
|
|
||||||||
Corporate and other expenses |
$ |
(18.2 |
) |
$ |
(15.0 |
) |
|
$ |
(36.0 |
) |
$ |
(30.5 |
) |
Depreciation and amortization |
|
0.9 |
|
|
1.0 |
|
|
|
1.8 |
|
|
2.2 |
|
Adjusted EBITDA Corporate |
$ |
(17.3 |
) |
$ |
(14.0 |
) |
|
$ |
(34.2 |
) |
$ |
(28.3 |
) |
|
|
|
|
|
|
||||||||
Pulp and Paperboard segment |
$ |
61.2 |
|
$ |
22.0 |
|
|
$ |
120.8 |
|
$ |
56.0 |
|
Consumer Products segment |
|
19.1 |
|
|
6.7 |
|
|
|
35.3 |
|
|
41.4 |
|
Corporate and other |
|
(17.3 |
) |
|
(14.0 |
) |
|
|
(34.2 |
) |
|
(28.3 |
) |
Adjusted EBITDA |
$ |
63.0 |
|
$ |
14.8 |
|
|
$ |
121.9 |
|
$ |
69.1 |
|
1 |
Other operating charges, net consist of amounts unrelated to ongoing core operating activities. Please refer to Note 8 within Clearwater Paper's Form 10-Q filed with the |
|
|||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||
(Unaudited) |
|||||||||||
|
|||||||||||
|
Quarter Ended |
|
Six Months Ended |
||||||||
(In millions, except per-share data) |
2022 |
2021 |
|
2022 |
2021 |
||||||
|
|
|
|
|
|
||||||
Adjusted net income (loss): |
|
|
|
|
|
||||||
Net income (loss) |
$ |
14.7 |
$ |
(51.6 |
) |
|
$ |
31.3 |
$ |
(39.6 |
) |
Add back: |
|
|
|
|
|
||||||
Income tax provision (benefit) |
|
4.4 |
|
(16.7 |
) |
|
|
10.4 |
|
(13.5 |
) |
Income (loss) before income taxes |
|
19.1 |
|
(68.4 |
) |
|
|
41.7 |
|
(53.1 |
) |
|
|
|
|
|
|
||||||
Add back: |
|
|
|
|
|
||||||
Debt retirement costs |
|
0.3 |
|
— |
|
|
|
0.5 |
|
— |
|
Other operating charges, net |
|
5.7 |
|
44.5 |
|
|
|
6.3 |
|
44.9 |
|
Adjusted income (loss) before tax |
$ |
25.2 |
$ |
(23.8 |
) |
|
$ |
48.5 |
$ |
(8.2 |
) |
Normalized income tax provision |
|
6.3 |
|
(6.0 |
) |
|
|
12.1 |
|
(2.0 |
) |
Adjusted net income (loss) |
$ |
18.9 |
$ |
(17.9 |
) |
|
$ |
36.4 |
$ |
(6.1 |
) |
|
|
|
|
|
|
||||||
Weighted average diluted shares (thousands) |
|
17,078 |
|
16,685 |
|
|
|
17,080 |
|
16,678 |
|
|
|
|
|
|
|
||||||
Adjusted income (loss) per diluted share |
$ |
1.11 |
$ |
(1.07 |
) |
|
$ |
2.13 |
$ |
(0.37 |
) |
|
|
|
|
|
|
||||||
|
|
|
|
|
|
||||||
Calculation of net debt: |
|
|
|
|
|
||||||
Current portion long-term debt |
$ |
1.0 |
$ |
1.6 |
|
|
$ |
1.6 |
|
||
Long-term debt |
|
589.9 |
|
617.7 |
|
|
|
637.6 |
|
||
Add back: |
|
|
|
|
|
||||||
Unamortized deferred debt costs |
|
3.8 |
|
4.4 |
|
|
|
4.8 |
|
||
Less: |
|
|
|
|
|
||||||
Financing leases |
|
24.7 |
|
18.7 |
|
|
|
19.1 |
|
||
Cash and cash equivalents |
|
69.5 |
|
36.4 |
|
|
|
25.2 |
|
||
Net debt |
$ |
500.5 |
$ |
568.6 |
|
|
$ |
599.8 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005929/en/
Investors
Solebury Trout
509-344-5906
investorinfo@clearwaterpaper.com
News media
509-344-5967
shannon.myers@clearwaterpaper.com
Source:
FAQ
What were Clearwater Paper's Q2 2022 net sales?
How did Clearwater Paper perform in terms of net income in Q2 2022?
What is Clearwater Paper's adjusted EBITDA for Q2 2022?
How much did Clearwater Paper reduce its net debt in Q2 2022?